ATE236987T1 - Konsensus-kozak-sequenzen zur säugetier- exprimierung - Google Patents

Konsensus-kozak-sequenzen zur säugetier- exprimierung

Info

Publication number
ATE236987T1
ATE236987T1 AT94901599T AT94901599T ATE236987T1 AT E236987 T1 ATE236987 T1 AT E236987T1 AT 94901599 T AT94901599 T AT 94901599T AT 94901599 T AT94901599 T AT 94901599T AT E236987 T1 ATE236987 T1 AT E236987T1
Authority
AT
Austria
Prior art keywords
atg
consensus kozak
disclosed
nucleotide
pyxx
Prior art date
Application number
AT94901599T
Other languages
English (en)
Inventor
Mitchell E Reff
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/147,696 external-priority patent/US5648267A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Application granted granted Critical
Publication of ATE236987T1 publication Critical patent/ATE236987T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Image Analysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94901599T 1992-11-13 1993-11-12 Konsensus-kozak-sequenzen zur säugetier- exprimierung ATE236987T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97769192A 1992-11-13 1992-11-13
US08/147,696 US5648267A (en) 1992-11-13 1993-11-03 Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
PCT/US1993/011221 WO1994011523A2 (en) 1992-11-13 1993-11-12 Fully impaired consensus kozac sequences for mammalian expression

Publications (1)

Publication Number Publication Date
ATE236987T1 true ATE236987T1 (de) 2003-04-15

Family

ID=26845148

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94901599T ATE236987T1 (de) 1992-11-13 1993-11-12 Konsensus-kozak-sequenzen zur säugetier- exprimierung

Country Status (8)

Country Link
US (3) US5733779A (de)
EP (1) EP0669986B1 (de)
AT (1) ATE236987T1 (de)
CA (1) CA2149326C (de)
DE (2) DE669986T1 (de)
DK (1) DK0669986T3 (de)
ES (1) ES2088838T3 (de)
PT (1) PT669986E (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086527A (en) 1998-04-02 2000-07-11 Scimed Life Systems, Inc. System for treating congestive heart failure
HK1043312B (en) * 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US20050144655A1 (en) * 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
ATE443131T1 (de) * 2001-07-10 2009-10-15 Biogen Idec Inc Hemmung des apoptoseprozesses und verbesserung der zelleistung
IL161988A0 (en) 2001-11-16 2005-11-20 Corporation Idec Pharmaceutica Polycistronic expression of antibodies
WO2003072739A2 (en) * 2002-02-25 2003-09-04 Intronn, Inc. Trans-splicing mediated imaging of gene expression
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2003290453A1 (en) 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
MXPA05007940A (es) * 2003-01-27 2007-06-14 Biogen Idec Inc Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
EP2902491A1 (de) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO Rezeptor bindendes Protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
EP1660654B1 (de) 2003-09-04 2011-11-09 Medarex, Inc. Expressionsvektor
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
EP1776136B1 (de) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
US20060172382A1 (en) * 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
AU2005300503B2 (en) 2004-11-08 2010-12-16 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) * 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP2311880A3 (de) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto-bindende Moleküle
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
AU2006311828B2 (en) 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
EP1806365A1 (de) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
JP5829373B2 (ja) 2006-01-27 2015-12-09 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｎｏｇｏレセプターアンタゴニスト
EA200802061A1 (ru) * 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
EP2099826B1 (de) 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid-antikörper und verwendung davon
ES2464815T3 (es) 2007-01-09 2014-06-04 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
UA99452C2 (ru) 2007-02-02 2012-08-27 Байоджэн Айдэк Ма Инк. Способ стимулирования миелинизации и дифференцирования олигодендроцитов путем применения семафорина 6a
US20090130105A1 (en) * 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
WO2009032145A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
CN102065895A (zh) * 2008-04-11 2011-05-18 比奥根艾迪克Ma公司 抗-igf-1r抗体和其它化合物的治疗联合
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
US20100081789A1 (en) * 2008-09-25 2010-04-01 Cooper Richard K Novel Vectors for Production of Interferon
US9157097B2 (en) * 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
EP3521309A1 (de) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
CN102365364B (zh) 2009-03-31 2015-01-21 株式会社斯特利恩 用于选择高效表达重组细胞系的方法
EP2417263B1 (de) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Herstellung von proteinen unter verwendung von vektoren auf transposonbasis
SI2462237T1 (sl) * 2009-08-06 2016-04-29 Cmc Icos Biologics, Inc. Postopki za izboljšanje ekspresije rekombinantnega proteina
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
EP2651979B1 (de) 2010-12-17 2019-08-28 Neurimmune Holding AG Humane anti-sod-1 antikörper
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CA2887682A1 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EA201790165A1 (ru) 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение
AU2015326911C1 (en) 2014-09-30 2025-12-18 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
BR112019000630A2 (pt) 2016-07-13 2019-07-09 Biogen Ma Inc regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3576762A1 (de) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Faktor-ix-fusionsproteine und verfahren zur herstellung und verwendung davon
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
CA3097872A1 (en) 2018-04-27 2019-10-31 Biogen Ma Inc. Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
AR126845A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Producción de adn de extremo cerrado con secuencias repetidas de terminal invertida
EP4408874A1 (de) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Faktor viii polypeptid kodierende nukleinsäuren mit verminderter immunogenität

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same

Also Published As

Publication number Publication date
DK0669986T3 (da) 2003-07-28
CA2149326A1 (en) 1994-05-26
ES2088838T3 (es) 2004-01-01
EP0669986B1 (de) 2003-04-09
PT669986E (pt) 2003-08-29
EP0669986A1 (de) 1995-09-06
US6017733A (en) 2000-01-25
DE69332859D1 (de) 2003-05-15
DE669986T1 (de) 1996-10-10
CA2149326C (en) 2007-04-17
US5733779A (en) 1998-03-31
US6159730A (en) 2000-12-12
DE69332859T2 (de) 2003-12-18
ES2088838T1 (es) 1996-10-01

Similar Documents

Publication Publication Date Title
DE69332859D1 (de) Konsensus-kozak-sequenzen zur säugetier-exprimierung
WO1994011523A3 (en) Fully impaired consensus kozac sequences for mammalian expression
Nakashima et al. Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells
Miyata et al. Nucleotide sequence divergence of mouse immunoglobulin gamma 1 and gamma 2b chain genes and the hypothesis of intervening sequence-mediated domain transfer.
BR9508033A (pt) Cassete de expressão de dna vetor de expressão de levedura célula de levedura processo para produzir um polipeptídeo em levedura
CO4960642A1 (es) Inhibidores de proteino farnesil transferasas inhibidores de la proteinofarnesiltransferasa y composicio nes que los ocntienen
AU658634B2 (en) Synthetic catalytic oligonucleotide structures containing modified nucleotides
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
ATE66693T1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
DK0597960T3 (da) Behandling af cellepopulationer
DE69730592D1 (de) Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
Carper et al. cDNA sequence of a human heat shock protein HSP27
EP0290419A2 (de) DNS-Klone von menschlichem Thrombomodulin
DE69936919D1 (en) Fy7 polymerase
Leder et al. Characterization, expression, and evolution of the mouse embryonic ζ-globin gene
IL128198A (en) Isolated nucleic acids and uses thereof for conferring plants with resistance to nematodes and/or aphids
AU2890497A (en) Nucleoside derivatives with photolabile protective groups
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
Ogawa et al. Molecular cloning, sequence analysis, and expression in Escherichia coli of the cDNA for guanidinoacetate methyltransferase from rat liver.
DE69233612D1 (de) Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz
ATE296886T1 (de) Männliche fertilität vermittelnde nukleotidsequenzen und verfahren zu ihrer verwendung
TW343997B (en) Mutant AOX2 promoter, vector carrying same, transformant, and production of heterologous protein
DE3885395D1 (de) Expressionsvektor und Verfahren zur Expression von heterologen Proteinen in Säugerzellen.
DK0981537T3 (da) Smitsom klon af humant parainfluenzavirus type 3

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0669986

Country of ref document: EP